Header Logo

Connection

Andrew South to Angiotensin-Converting Enzyme Inhibitors

This is a "connection" page, showing publications Andrew South has written about Angiotensin-Converting Enzyme Inhibitors.
  1. South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. Hypertension. 2020 07; 76(1):16-22.
    View in: PubMed
    Score: 0.802
  2. Cohen JB, Hanff TC, South AM, Sparks MA, Hiremath S, Bress AP, Byrd JB, Chirinos JA. Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". Circ Res. 2020 06 05; 126(12):e140-e141.
    View in: PubMed
    Score: 0.202
  3. Sparks MA, South A, Welling P, Luther JM, Cohen J, Byrd JB, Burrell LM, Batlle D, Tomlinson L, Bhalla V, Rheault MN, Soler MJ, Swaminathan S, Hiremath S. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clin J Am Soc Nephrol. 2020 May 07; 15(5):714-716.
    View in: PubMed
    Score: 0.199
  4. South AM, Arguelles L, Finer G, Langman CB. Race, obesity, and the renin-angiotensin-aldosterone system: treatment response in children with primary hypertension. Pediatr Nephrol. 2017 09; 32(9):1585-1594.
    View in: PubMed
    Score: 0.162
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.